the market doesnt, but i really see the Hylid agreement as being huge. like you said, we arent doing it alone on this one, we are joing forced with a much more developed product. Sure this means far less revenue for archer, but its revenue. And i dont see the capabilities of the chip stopping at Kidney and potassium samples. This is the beginning.
Even better if it grown with Hylid, and our piece of the pie gets bigger when not piggybacking one of their own products.
AXE Price at posting:
25.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)